CYduct Diagnostics Inc. Provides a Corporate Outlook for 2023
CYduct Diagnostics, Inc. (OTC PINK:CYDX) has provided a corporate outlook for 2023, emphasizing a commitment to advancing innovative healthcare products. In 2022, the company focused on enhancing its current offerings and initiating new product candidates. Key initiatives for 2023 include:
- Conducting clinical trials for B-FIRST™, a breast cancer risk assessment product.
- Developing a Point-of-Care proteomic device using patented nano sensor technology.
- Partnering with a leading biomedical engineering firm.
- Applying for an NIH grant for product development.
Overall, CYduct aims to enhance shareholder value while accelerating research and development in breast healthcare.
- Initiation of a clinical trial for B-FIRST™, advancing breast cancer risk assessment.
- Development of a revolutionary Point-of-Care proteomic device using nano sensor technology.
- Focus on partnerships with biomedical engineering firms to enhance product efficacy.
- Plans to apply for NIH grant funding to support product research and commercialization.
- None.
Insights
Analyzing...
WESTPORT, CT / ACCESSWIRE / January 19, 2023 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct" or the "Company"), is a company focused on developing life-enhancing breast healthcare products, and today provides an update on its corporate guidance outlook for 2023. The Company's corporate strategy remains focused on maximizing performance of its current products and its new breast healthcare product candidates, while prioritizing shareholder value and delivering key sustainability initiatives.
"Following a year of continued strong execution, our progress in 2022 has set the stage for a significant year in which we plan to further advance the potential of our new product candidate, B-FIRST™, for use in proteomic breast cancer risk assessment testing and initiate the first clinical trial for our risk assessment program," stated Dominick Gatto, Chief Executive Officer. "Our focus remains on advancing and verifying the value of our proprietary product candidates, which we believe have the potential to deliver new, life-saving diagnostics for women, significantly improving the risk stratification of breast cancer, helping to personalize breast cancer screening and detection, thus opening new frontiers in early oncoproteomics," he continued.
The Company expects that there will be several key initiatives over the next twelve months that can be used to measure the Company's progress. This year the Company expects key data analysis from its initial study of biomarkers for the risk assessment of breast cancer, as well as from the Company's proof-of-concept trial of its microfluidic proteomic sample collection device. Additionally, the Company expects to initiate the first clinical trial of B-FIRST later in the year. Importantly, the Company believes its strong team provides the Company with the ability to execute its plans well beyond these key initiatives and build momentum to carry it well into 2024.
The Company has several corporate initiatives for 2023 including:
Continue the actions necessary to develop what the Company believes will be a revolutionary Point-of-Care proteomic breast cancer risk assessment device that will utilize patented nano sensor technology.
- Apply for an NIH grant to further the development and research of the Company's breast cancer risk assessment platform product with the goal of commercialization.
- Engage a leading biomedical engineering firm to design and test CYduct's proprietary microfluidic collection device.
- Begin testing of the Company's first patient samples to detect targeted biomarkers associated with breast cancer.
- Establish partnership with a leading CLIA clinical laboratory with testing services in the areas of proteomics and assay development.
- Add key members to the Company's management team.
- Establish a distribution network globally for the Company's surgical breast products.
We encourage shareholders to visit our official corporate social media account for updates, provided that information on platforms is not incorporated into this press release:
https://twitter.com/CYductDx
https://www.linkedin.com/company/cyductdx/
https://www.facebook.com/CYductDiagnostics
About CYduct Diagnostics, Inc.:
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof, and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc
View source version on accesswire.com:
https://www.accesswire.com/735835/CYduct-Diagnostics-Inc-Provides-a-Corporate-Outlook-for-2023
FAQ
What is CYduct Diagnostics' outlook for 2023?
What key initiatives is CYduct Diagnostics pursuing in 2023?
What is the significance of the B-FIRST™ product for CYduct Diagnostics?
How does CYduct Diagnostics plan to improve breast healthcare?
What partnerships is CYduct Diagnostics pursuing for its products?
